Lenalidomide is related to [[thalidomide]] which is known to be [[teratogen]]ic. Tests in monkeys have suggested lenalidomide is also [[teratogen]]ic.<ref>{{cite web|title=Revlimid Summary of Product Characteristics. Annex I|year=2012|publisher=[[European Medicines Agency]]|page=6|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf}}</ref> It therefore has the [[pregnancy category]] X  and cannot be prescribed for women who are pregnant or who might be conceiving. For this reason, the drug is only available in the [[United States]] (under the name Revlimid) through a restricted distribution system called RevAssist.

 


 
Other potential side effects are [[thrombosis]], [[pulmonary embolus]], and [[hepatotoxicity]], as well as bone marrow toxicity resulting in [[neutropenia]] and [[thrombocytopenia]]. [[Myelosuppression]] is the major dose-limiting toxicity, which is contrary to experience with thalidomide.<ref>{{cite journal

 
| author = Rao KV

 
| title = Lenalidomide in the treatment of multiple myeloma

 
| journal = American Journal of Health-System Pharmacy

 
| volume = 64

 
| issue = 17

 
| pages = 1799â€“807

 
|date=September 2007

 
| pmid = 17724360

 
| doi = 10.2146/ajhp070029

 
}}</ref>

 

